The DOI matches its Crossref record.
Application of lag‐time into exposure definitions to control for protopathic bias
Abstract
Purpose: To control for protopathic bias, some studies have incorporated the concept of lag‐time into their exposure definition (time period before the index date that was not considered in assessing exposure). The objective of this study was to introduce a procedure to identify the best lag‐time to be applied in studies where control for protopathic bias is required. Methods: We used data from a case‐control study carried out to assess the association between exposure to proton pump inhibitors (PPIs) and risk of gastric cancer, using RAMQ databases. Exposure was defined as the number of defined daily doses of PPIs dispensed during the 5‐year period prior to the index date (divided into four quartiles). Thirty‐one different lag‐times were applied (0–30 months) based on 1‐month intervals. Logistic regression was used to estimate the matched odds ratio (OR) for each lag‐time. The change point in the ln(ORs) was identified by applying a two‐compartmental model and a segmented regression model. Results: A trend of decreasing ORs was found with the application of an increasing lag‐time. As an illustration, the ORs for the 1st quartile of defined daily doses, when applying the 31 different lag‐times, ranged between 3.52 when applying a 0 lag‐time and 0.97 when applying a 30 months lag‐time. Applying the two methods for the different lag‐times showed that the ORs stabilized at around 6 months. Conclusion: For the purpose of controlling for protopathic bias in pharmacoepidemiological studies, we have provided a method to assess the most appropriate lag‐time that should be applied for the assessment of drug exposure. Copyright © 2007 John Wiley & Sons, Ltd.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The primary measure of anticholinergic use was 10-year cumulative exposure, and prescription fills in the most recent 1 year period were excluded because of concern about protopathic bias.
“The primary measure of anticholinergic use was 10-year cumulative exposure (eFigure 2). Prescription fills in the most recent 1 year period were excluded because of concern about protopathic bias.30”
From Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study (2015) · cites this paper as [30]
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 22
- 10.1002/0470842555 · DOI
- 10.1016/0002-9343(80)90363-0 · DOI · Paper page
- 10.1186/1471-2407-3-28 · DOI
- 10.1016/S1086-5802(16)31036-1 · DOI
- 10.3322/canjclin.53.1.5 · DOI · Paper page
- 10.1007/s10120-002-0203-6 · DOI
- 10.1016/0895-4356(94)00234-H · DOI · Paper page
- Tamim HM, 2005, Case‐control study of the association between use of acid suppressive drugs and risk of gastric cancer (Abstract), Can J Clin Pharmacol, 12
- SAS Institute, Inc, 1999, The SAS System for Windows Software, Release 8.2
- Hanushek EA, 1977, Statistical Methods for Social Scientists
- 10.1093/pan/mpi026 · DOI
- 10.2307/2290002 · DOI
- Jacquez JA, 1996, Compartmental Analysis in Biology and Medicine
- Jacquez JA, 1999, Modeling with Compartments
- 10.1109/TAC.1974.1100705 · DOI · Paper page
- Draper NR, 1981, Applied Regression Analysis
- 10.1080/03610929208830920 · DOI
- 10.1080/01621459.1966.10482198 · DOI
- 10.1002/sim.4780100306 · DOI
- 10.2307/1912934 · DOI · Paper page
- 10.1038/clpt.1988.142 · DOI
- Drusano GL, 1994, Optimal sampling theory: effect of error in a nominal parameter value on bias and precision of parameter estimation, Clin Pharmacol Ther, 34, 967
Cited by
Sorted by citations
Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study
Gray, S. L., Anderson, M. L., Dublin, S., Hanlon, J. T., Hubbard, R., Walker, R., Yu, O., Crane, P. K., & Larson, E. B. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.7663 · Cited by 1,111
Cheung, K. S., Chan, E. W., Wong, A. Y. S., Chen, L., Wong, I. C. K., & Leung, W. K. (2018) · Gut · doi:10.1136/gutjnl-2017-314605 · Cited by 455
Risnes, K. R., Belanger, K., Murk, W., & Bracken, M. B. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwq400 · Cited by 297
Gray, S. L., Dublin, S., Yu, O., Walker, R., Anderson, M., Hubbard, R. A., Crane, P. K., & Larson, E. B. (2016) · BMJ · doi:10.1136/bmj.i90 · Cited by 233
Duration of antihypertensive drug use and risk of dementia: A prospective cohort study
Haag, M. D. M., Hofman, A., Koudstaal, P. J., Breteler, M. M. B., & Stricker, B. H. C. (2009) · Neurology · doi:10.1212/01.wnl.0000345062.86148.3f · Cited by 140
Wu, C.-Y., Iskander, C., Wang, C., Xiong, L. Y., Shah, B. R., Edwards, J. D., Kapral, M. K., Herrmann, N., Lanctôt, K. L., Masellis, M., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1705 · Cited by 139
Movahedi, M., Costello, R., Lunt, M., Pye, S. R., Sergeant, J. C., & Dixon, W. G. (2016) · European Journal of Epidemiology · doi:10.1007/s10654-016-0167-1 · Cited by 58
Richardson, K., Mattishent, K., Loke, Y. K., Steel, N., Fox, C., Grossi, C. M., Bennett, K., Maidment, I., Boustani, M., Matthews, F. E., et al. (2019) · American Journal of Epidemiology · doi:10.1093/aje/kwz073 · Cited by 36
Pai, Y., Chen, I., Lin, J., Chen, X., Chen, H., Chang, M., Huang, J., & Lin, C. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15918 · Cited by 26
Metadata
- Authors
- Tamim, H., Monfared, A. A. T., & LeLorier, J.
- Affiliations
- Hôtel-Dieu de Montréal (CA)
- Montreal General Hospital (CA)
- Corresponding author
- LeLorier, J.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2007-01-24
- Volume
- 16
- Issue
- 3
- Pages
- 250-258
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W2058823385
- Cited by
- 186
- References
- 0
- Citations by year
- 2026: 21 · 2025: 9 · 2024: 12 · 2023: 19 · 2022: 14 · 2021: 15 · 2020: 9 · 2019: 18 · 2018: 10 · 2017: 11 · 2016: 9 · 2015: 9 · 2014: 6 · 2013: 3 · 2012: 2
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacoepidemiology and Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Physical Sciences › Mathematics › Statistics and Probability › Advanced Causal Inference Techniques
- Keywords
- protopathic bias, time delay, exposure definition, proton pump inhibitors, gastric cancer, defined daily doses, segmented regression, two-compartment model, pharmacoepidemiology
- MeSH terms
- Anti-Ulcer Agents, Humans, Research Design, Stomach Neoplasms, Time Factors, Models, Statistical, Bias, Logistic Models, Odds Ratio, Epidemiologic Studies, Case-Control Studies, Proton Pumps, Pharmacoepidemiology, Proton Pump Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review